Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Madan Jagasia

8 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCBMT1063

07/27/2011

T-Regulatory Homing Subsets as a Predictor of Response in GVHD Treated with Extracorporeal Photopheresis

Other

VICCBMT1401

08/29/2014

Prospective Outcomes of Second-Line Therapy in Acute Graft-versus-Host Study Including ECP (POSTAGE)

Other

VICCBMT1380

02/05/2014

Chronic GVHD Response Measures Validation

Supportive Care

VICCBMT1335

02/18/2014

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP01113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Supportive Care

VICCBMT12104

02/04/2014

Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease (GVHD)

Supportive Care

VICCBMT1218

09/04/2012

A Randomized, Prospective, Double Blind, Placebo-Controlled, Phase 3 Study of US-ATG-F Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients after Allogeneic Stem Cell Transplantation from Unrelated Donors

Treatment

VICCHEM12107

03/31/2013

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LD-DEX) versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (MM)

Treatment

VICCBMT1020

11/15/2010

Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment with Velcade Based Therapy